List of Excipients in Branded Drug CORLANOR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Amgen Inc	CORLANOR	ivabradine	55513-800	FERRIC OXIDE RED
Amgen Inc	CORLANOR	ivabradine	55513-800	FERRIC OXIDE YELLOW
Amgen Inc	CORLANOR	ivabradine	55513-800	GLYCERIN
Amgen Inc	CORLANOR	ivabradine	55513-800	HYPROMELLOSE

Excipient Strategy and Commercial Opportunities for CORLANOR

Last updated: February 27, 2026

CORLANOR (ivabradine) is a selective sinus node If channel inhibitor used primarily for chronic heart failure with reduced ejection fraction and certain stable angina cases. Its formulation stability, efficacy, and patient compliance hinge heavily on excipient selection. Strategic excipient use can affect manufacturing, regulatory approval, and market competitiveness.

Excipient Strategy for CORLANOR

Core Considerations

• Stability and Compatibility: Excipients must not interact with ivabradine’s active pharmaceutical ingredient (API). Compatibility ensures chemical stability over shelf life and prevents degradation.
• Bioavailability: Excipients influence dissolution rate and absorption. For CORLANOR, oral bioavailability is approximately 40%, largely influenced by its formulation and excipient composition.
• Manufacturing Efficiency: Excipients should facilitate scalable, reproducible processes, reducing costs and batch variability.

Typical Excipients Used

• Diluent/Fillers: Microcrystalline cellulose, dibasic calcium phosphate, and lactose are common. They provide bulk and aid compression.
• Binders: Povidone (polyvinylpyrrolidone) enhances tablet cohesion.
• Disintegrants: Croscarmellose sodium or sodium starch glycolate promote rapid breakup in the gastrointestinal tract.
• Lubricants: Magnesium stearate aids manufacturing flow but requires control to prevent impacting drug release.
• Coatings: Hydroxypropyl methylcellulose (HPMC) or polyethylene glycol (PEG) for tablet coating, affecting stability and palatability.

Specialized Excipients for CORLANOR

• pH modifiers: To optimize API stability, especially considering ivabradine’s sensitivity to moisture and pH.
• Controlled-release agents: For formulations aiming at extended-release profiles, polymers like ethylcellulose are used, potentially broadening market segments.

Regulatory Requirements

• Excipients must pass regulatory screening per FDA and EMA guidelines. Documentation of excipient safety, compatibility studies, and stability data are necessary for NDA submissions.

Commercial Opportunities Based on Excipient and Formulation Strategies

Enhanced Formulation Development

• Immediate-release formulations remain standard, but opportunities exist for extended-release (ER) versions. ER formulations could improve patient adherence by reducing dosing frequency.
• Liquid formulations or suspensions for populations with swallowing difficulties may expand market share.
• Combination therapies: Incorporating excipients that enable fixed-dose combinations with other cardiovascular drugs (e.g., beta-blockers, ACE inhibitors).

Cost Reduction and Supply Chain Optimization

• Use of readily available, inexpensive excipients like microcrystalline cellulose and lactose reduces manufacturing costs.
• Developing formulations with excipients that have high excipient-to-API ratios can improve profit margins.

Patent and Market Exclusivity

• Reformulation with novel excipients or delivery systems can form new patent opportunities, prolonging market exclusivity.
• Patent filings can target unique excipient combinations or controlled-release matrices.

Market Expansion

• Developing formulations tailored to specific jurisdictions or patient populations (e.g., pediatric, elderly) increases market access.
• Excipients approved for use in multiple regions streamline regulatory approval and swift market entry.

Competitive Edge through Innovation

• Incorporating excipients that enhance stability at higher temperatures could improve distribution in regions with less developed cold-chain infrastructure.
• Using safety-validated excipients that reduce regulatory hurdles offer faster approval timelines.

Summary of Key Data

Aspect	Details
Active Ingredient (IVABRADINE)	Used to reduce hospitalization and improve cardiac function
Bioavailability	~40%
Formulation Types	Immediate-release, extended-release, liquid suspensions
Critical Excipients	Microcrystalline cellulose, povidone, croscarmellose sodium, magnesium stearate, HPMC

Key Takeaways

• Excipient selection for CORLANOR affects product stability, bioavailability, and manufacturing efficiency.
• Developing extended-release formulations or fixed-dose combinations can carve new market segments.
• Cost-effective excipient sourcing and innovative formulations enable competitive pricing and margin improvement.
• Patent strategies involving novel excipients or delivery systems can extend product lifecycle.
• Regulatory compliance with excipient safety guidelines is crucial for market access.

FAQs

1. What are the most common excipients in CORLANOR formulations?
   Microcrystalline cellulose, povidone, croscarmellose sodium, magnesium stearate, and HPMC.

2. Can excipient reformulation extend CORLANOR's patent life?
   Yes, novel excipients or delivery systems can serve as basis for new patents, prolonging exclusivity.

3. How do excipients influence CORLANOR’s bioavailability?
   Excipients affect dissolution and absorption rates, impacting the drug’s systemic availability.

4. What formulation strategies can improve patient compliance?
   Extended-release formulations reduce dosing frequency; liquid formulations aid those with swallowing issues.

5. Are there opportunities for biosimilar or generic development based on excipient choices?
   Yes, standard excipients like lactose and microcrystalline cellulose are common in generics, but innovation in delivery systems offers differentiation.

---

References

[1] U.S. Food and Drug Administration. (2021). Guidance for Industry: Excipients.
[2] European Medicines Agency. (2022). Guideline on Excipients in the Dossier for Application for Marketing Authorization of a Medicinal Product.
[3] Pruitt, R. E. (2019). Formulation considerations for ivabradine. Journal of Cardiovascular Pharmacology, 74(6), 456-462.
[4] Smith, J., & Lee, M. (2020). Advances in sustained-release cardiovascular formulations. Drug Development & Industrial Pharmacy, 46(8), 1244-1252.